CSL Shares CSL Limited
BUY ASX · ASXInstitutional overweighting, sector leadership, supportive pipeline deal, and improving healthcare momentum support recovery potential.
Future value: $186.27 (-5.34%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Institutional accumulation and Morgans buy rating with $187.71 target
- ▸Above 50-day MA (+10.19%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (86.2% of range) — strength
- ▾Trading above its price target — limited upside
Is CSL a buy right now?
Trend: CSL is trading above the 50-day average (+8.82%), RSI 16 — oversold territory, with a 3-month return of +52.54%.
Valuation & quality: CSL Limited trades on forward P/E 20.5, PEG 1.82, price-to-book 4.40; fundamentals show net margin -16.3%, return on equity -15.8%, revenue growth 5.5% year on year.
Analyst consensus: 17 analysts have a mean 12-month price target of A$186.34 (-5.3% vs the last close; range A$151.95 – A$215.20), consensus rating “buy”.
Income: trailing dividend yield 2.06%.
Our screen: BUY (score 3) — Institutional overweighting, sector leadership, supportive pipeline deal, and improving healthcare momentum support recovery potential.
Computed from end-of-day data; not personal advice.
Our track record with CSL
Our simulated $10,000 funds have traded CSL 3 times — 1 of 1 closed trade profitable, 2 positions still open.
| Fund | Bought | Sold | Return |
|---|---|---|---|
| ASX High-risk | 2026-10-08 @ $181.46 | Still held · $195.14 | +7.54% |
| ASX Low-risk | 2026-08-27 @ $173.08 | Still held · $195.14 | +12.75% |
| ASX Medium-risk | 2026-08-22 @ $169.45 | 2026-10-26 @ $195.14 · AI review sell | +15.16% |
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -3.10% | -12.50% | -22.30% | +18.80% | +7.30% | +39.40% | +7.40% | +5.90% |
Fundamentals
Analyst price target
Technical signals
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
Sector: Healthcare · Industry: Biotechnology · Australia · 29,000 employees · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.